“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
CanSino Biologics Inc (OTC: CASBF) has the first company to download a patent for its COVID-19 vaccine in China, Reuters reported sunday.
What happened
The company’s patent, based in Tianjin, China, for its Ad5-nCOV vaccine opposed to COVID-19, approved through China’s National Intellectual Property Administration on August 11, according to Reuters.
Saudi Arabia last month announced its goal of testing the CanSino vaccine in phase 3 trials. The company would also negotiate with Brazil, Chile and Russia to launch tests.
Why it’s important
In May, the Chinese vaccine manufacturer’s application for a Phase 2 clinical trial was approved by Canada’s federal fitness regulator.
Several candidate vaccines from corporations such as Pfizer Inc (NYSE: PFE) and their spouse BioNTech SE (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), Johnson and Johnson (NYSE: JNJ) are on or near the overdue tests.
The UK government will conduct the phase 3 trial of the Novavax, Inc. vaccine (NASDAQ: NVAX) as a component of an origin agreement with the company.
AstraZeneca plc (NYSE: AZN) signed an agreement with the governments of Mexico and Argentina for its future COVID-19 vaccine for Latin American countries, with the exception of Brazil.
Russia claims that its “Sputnik V” vaccine is available for immediate use, but the lack of a Phase 3 trial leads to a department among protection experts.
Price action
CanSino OTC shares closed Friday with a drop of about 2.6% to $25.36.
Photo courtesy: National Cancer Institute Wikimedia
Meet Benzinga
Telegram video calls to your messaging app
Facebook denounces Apple’s App Store tax on its initiative to help small businesses pandemic
Amazon faces German research into value controls on its platform amid a pandemic
© 2020 Benzinga.com. Benzinga offers investment advice. All rights are reserved.